# RASolute 309 (zoldonrasib): what clinicians are saying

> 25 statements from 25 sources (1 podcast, 5 videos, 18 posts, 1 registry record), 8 of them from 10 confirmed clinicians, each linked to its source. Commentary checked Nov 11, 2026.

## Report

- Trial: A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Patients With Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
- NCT ID: NCT07805954
- Registry: https://clinicaltrials.gov/study/NCT07805954
- Sponsor: Revolution Medicines, Inc.
- Phase: Phase 3
- Status: Recruiting
- Drugs tested: zoldonrasib plus daraxonrasib
- Indication: first-line metastatic KRAS G12D-mutated pancreatic adenocarcinoma
- Version: v1.0.0, edition 1
- Accepted: 2026-11-11 UTC
- Last checked: 2026-11-11 UTC
- Release hash: 202ec535a94bcf0a65ed95069c537c9369a97be42c522bfd9715e4f2d407ff9f

## Counts

- Commentary sources screened: 43
- Sources cited by verified statements: 25
- Verified statements: 25
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 8
- Findings: 3
- Named people in screened sources (unnamed speakers and accounts not counted): 17
- Speakers cited: 17
- Cited speakers with a verified identity: 15
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 10
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 10
- By role and specialty (the abstract's specialty counts):
  - 6 physician, Medical oncology
  - 4 physician, specialty not confirmed
- Organisational or shared accounts (not counted as people): 3

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

The clinicians cited see RASolute 309 as a possible route away from chemotherapy, drawing on earlier doublet activity rather than evidence warranting treatment change. Its position relative to mFOLFIRINOX and nalIRINOX remains unestablished, and hopes for wider access do not confirm availability. Activity and rash observations largely concern earlier studies or broader daraxonrasib use; no results from the trial itself were available in the sources reviewed for this edition.

## Question clinicians left open

What do clinicians need to see in RASolute 309’s PFS and OS results before using zoldonrasib plus daraxonrasib as a chemotherapy-free alternative to first-line gemcitabine plus nab-paclitaxel for metastatic KRAS G12D-mutated pancreatic adenocarcinoma?

From finding F1 (14 statements from 6 speakers in 12 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Speakers welcome a chemotherapy-free first-line possibility but await phase 3 confirmation
  - 14 statements from 6 speakers in 12 sources, 1 of them a podcast or video.
- F2. One LinkedIn account asks: why use GemNabTAX as the control rather than mFOLFIRINOX or nalIRINOX?
  - 5 statements from 2 speakers in 3 sources.
- F3. One LinkedIn account hopes for Brazilian study access; a UK account sees progress toward access
  - 4 statements from 1 speaker in 4 sources, 2 of them podcasts or videos.

The full report also has 6 findings about other patients, lines of treatment or settings, after these trial findings under “Beyond the trial population”. They are not counted or listed on this page.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 14 | 13 | 12 | 6 | 2 |
| F2 | 5 | 3 | 3 | 2 | 2 |
| F3 | 4 | 4 | 4 | 1 | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 8 | 3 | 0 | 1 | 2 | 17 | 3 | 10 posts and articles, 1 podcast or video, 1 registry |
| F2 | 0 | 1 | 0 | 1 | 3 | 5 | 0 | 2 posts and articles, 1 registry |
| F3 | 3 | 0 | 0 | 0 | 1 | 4 | 1 | 2 posts and articles, 2 podcasts and video |

### Trial dimensions

- Primary endpoint: Progression free survival (PFS): F1 (1 shared claims), F2 (1 shared claims)
- Primary endpoint: Overall survival (OS): F1 (1 shared claims), F2 (1 shared claims)
- Secondary endpoints: F1 (3 shared claims)
- Population and setting: F1 (1 shared claims), F2 (1 shared claims)
- The comparison: F1 (9 shared claims), F2 (2 shared claims)
- Safety and tolerability: F1 (1 shared claims)
- Design and conduct: F1 (1 shared claims), F2 (2 shared claims), F3 (1 shared claims)

## Abbreviations

- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- OS: overall survival
- PFS: progression-free survival

## Examples from the report

Statements as the report records them, by the speaker's role only. Full statements, speaker names and links to each source are in the report.

- Physician, US, identity checked against NPI · video · Jul 2026 (finding F1): A physician considers RASolute-309 one of the most exciting forthcoming studies and is very excited about its potential to improve outcomes for patients with KRAS G12D.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 3 | Titles free |
| Detailed analysis | 11 sections | Paid |
| Verified statements with short source quotes and links | 25 | Paid |
| Who said each statement: the cited speakers | 17 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 10 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 15 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 8 | Free |
| Sources with links | 25 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 10 of the 17 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

8 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Progression free survival (PFS) | discussed | 2 | 1 |
| Primary endpoint: Overall survival (OS) | discussed | 2 | 1 |
| Secondary endpoints | discussed | 3 | 4 |
| Population and setting | discussed | 2 | 2 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 10 | 10 |
| Safety and tolerability | discussed | 2 | 2 |
| Design and conduct | discussed | 4 | 3 |
| Other public accounts' launch and pipeline interpretations | discussed | 4 | 3 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 7 statements · 28%** (from 6 videos and episodes · about 1 per source) | | | |
| YouTube | 7 | 5 | 5 |
| Podcasts | 0 | 1 | 1 |
| **Posts · 17 statements · 68%** (from 18 posts · about 0.9 per source) | | | |
| X threads | 6 | 12 | 28 |
| LinkedIn posts | 11 | 6 | 7 |
| Bluesky threads | 0 | 0 | 2 |
| **Primary sources · 1 statement · 4%** (cited for context, not screened · from 1 source · about 1 per source) | | | |
| Registry (primary source, cited for context) | 1 | 1 | not screened |

- Screened window: 2026-04-16 to 2026-10-26
- Cited window: 2026-04-16 to 2026-10-16
- Retrieved: 2026-11-11

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Patients With Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
- Registry: NCT07805954 (https://clinicaltrials.gov/study/NCT07805954)
- Study IDs: RMC-9805-309
- Sponsor: Revolution Medicines, Inc.
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Recruiting
- Enrollment: 400 (estimated)
- Start: 2026-08-28 (actual)
- Primary completion: 2029-03 (estimated)
- Primary endpoint: Progression free survival (PFS) (Up to approximately 4 years)
- Primary endpoint: Overall survival (OS) (Up to approximately 4 years)
- Intervention: daraxonrasib (drug)
- Intervention: gemcitabine (drug)
- Intervention: nab-paclitaxel (drug)
- Intervention: zoldonrasib (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- 1 clinician view in the sources used in this report is not yet captured as evidence in this edition.
- 56 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 24 sources about other trials or topics are not included.
- The sources reviewed for this edition are a selected public-discussion sample, not a representative survey of HCP opinion; repeated posts and relays do not establish independent agreement.
- Some passages cannot be assigned to a named speaker. Participant lists, professional profiles and recurring transcript labels do not resolve those passages.
- Much of the efficacy, toxicity, patient-reported-outcome and practical-management discussion concerns pretreated doublet cohorts or daraxonrasib in other settings. Those observations do not establish outcomes for the first-line RASolute 309 combination.
- No exact-trial results publication or protocol document was available in the reviewed material. Regulatory and access statements are attributed to their sources and do not independently confirm approval, reimbursement or local availability of the doublet.
- Several comments are personal experience, preclinical interpretation, cross-study comparison or prospective expectation. Unspecified cohorts and slightly differing numerical accounts prevent treating them as a single comparative dataset.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-11 UTC: current edition
  - Routine maintenance: 1 fix (text):
    - 2026-11-11 UTC: A summary sentence now uses the wording of the finding it summarizes.

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-11 UTC. No changes.

## Offer

- Size: Focused · 25 verified statements · 8 from 10 confirmed clinicians
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $1,300
- 6 months of updates: $1,900
- 12 months of updates: $2,600
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (15 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/rasolute-309-nct07805954
- Agents: POST https://www.erudio.com/api/orders with {"report": "rasolute-309-nct07805954", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "organization": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user and a pay_url your own payment client can pay over HTTP 402 in USDC, with MPP (on Tempo) or x402 (on Base), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=rasolute-309-nct07805954

## Cite

Erudio Health. RASolute 309 (NCT07805954): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 11, 2026. https://www.erudio.com/reports/rasolute-309-nct07805954

## Questions

### How much does the RASolute 309 report cost?

One edition costs $750 (Focused · 25 verified statements · 8 from 10 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.

### What does the RASolute 309 report cover?

25 statements from 25 sources (1 podcast, 5 videos, 18 posts, 1 registry record), 8 of them from 10 confirmed clinicians, each linked to its source. Commentary checked Nov 11, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the RASolute 309 report?

Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "rasolute-309-nct07805954" }) previews it and create_order({ "report": "rasolute-309-nct07805954", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the RASolute 309 report?

Edition 1 (version 1.0.0), accepted Nov 11, 2026 UTC; last checked for new commentary Nov 11, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/rasolute-309-nct07805954.json
- Markdown: https://www.erudio.com/reports/rasolute-309-nct07805954.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/rasolute-309-nct07805954/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "rasolute-309-nct07805954"}`